DEFA14A

0000950170-23-032759.txt : 20230713 0000950170-23-032759.hdr.sgml : 20230713 20230713070702 ACCESSION NUMBER: 0000950170-23-032759 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20230713 DATE AS OF CHANGE: 20230713 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Iterum Therapeutics plc CENTRAL INDEX KEY: 0001659323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38503 FILM NUMBER: 231085728 BUSINESS ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 BUSINESS PHONE: (872) 225-6077 MAIL ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 FORMER COMPANY: FORMER CONFORMED NAME: Iterum Therapeutics Ltd DATE OF NAME CHANGE: 20151124 DEFA14A 1 itrm_defa14a_letter_call.htm DEFA14A DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )


Filed by the Registrant ☒		Filed by a Party other than the Registrant ☐

Check the appropriate box:


☐	Preliminary Proxy Statement


☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))


☐	Definitive Proxy Statement


☒	Definitive Additional Materials


☐	Soliciting Material under §240.14a-12

Iterum Therapeutics plc

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):


☒	No fee required.


☐	Fee paid previously with preliminary materials.


☐	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Iterum Therapeutics plc

Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 YW24 | +353-1-6694820 |

www.iterumtx.com

The following communication was sent or made available commencing on July 13, 2023

to certain shareholders of Iterum Therapeutics plc

July 13, 2023

VIA COURIER

[NAME]

[ADDRESS]

[CITY]

[STATE]

[ZIP]

Dear Shareholder:

Thank you for your continued support of Iterum Therapeutics plc (“Iterum Therapeutics”) as a shareholder.

We are writing to you in connection with the upcoming extraordinary general meeting of shareholders (“EGM”) on August 1, 2023.

This vote is very important to the future of Iterum Therapeutics and its shareholders, and I was hoping you had time over the next few weeks to speak with me about the EGM.

The sole purpose of the proposal before the EGM is to extend the current pre-emption rights opt-out that Iterum Therapeutics has had since 2015 and to expand the opt-out to cover the additional shares authorized in May. Irish law requires the Iterum gets a super-majority vote of 75% in favor of this proposal.

As a reminder, Iterum Therapeutics’ shareholders granted the company the authority to issue up to an additional 60,000,000 shares at the annual shareholders meeting held in May of this year. The Board can still issue these newly approved shares even without the proposed pre-emption rights opt-out. However, such an issuance would entail a more onerous, drawn out, costly process for Iterum Therapeutics, which would likely result in more dilution to shareholders.

Approval of this proposal will allow us to continue to execute our business strategy. This includes the continued clinical development of oral sulopenem which is currently being evaluated in a Phase 3 clinical trial for the treatment of uncomplicated urinary tract infection in adult women.

Iterum Therapeutics is listed in the U.S. on the Nasdaq Capital Market, and as such, must follow U.S. capital markets practices and governance standards, similar to our U.S. incorporated peer companies. This pre-emption opt-out approval is required solely because we are incorporated in Ireland. Companies incorporated in the United States are not subject to similar share issuance restrictions.

I have enclosed with this letter a copy of the presentation made available to shareholders on our website summarizing the proposal to be put before the shareholders at the EGM.

I ask that you please contact me at +1 (312) 778-6073 as soon as you receive this letter so that we can discuss this extremely important matter.

Again, thank you for your continued support of Iterum Therapeutics.

Iterum Therapeutics plc

Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 YW24 | +353-1-6694820 |

www.iterumtx.com

Very truly yours,

Judith Matthews

Chief Financial Officer

Enclosures (2)

Iterum Therapeutics plc

Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 YW24 | +353-1-6694820 |

www.iterumtx.com

GRAPHIC 2 img214826273_0.jpg GRAPHIC begin 644 img214826273_0.jpg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end GRAPHIC 3 img214826273_1.jpg GRAPHIC begin 644 img214826273_1.jpg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end GRAPHIC 4 img214826273_2.jpg GRAPHIC begin 644 img214826273_2.jpg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end